Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Understand and voluntarily sign an informed consent document prior to any study-related assessments/procedures are conducted~2. 20 years or older, with histological or cytological confirmation of advanced solid tumors or Non-Hodgkin's Lymphoma (NHL), including those who have progressed on standard anticancer therapy or for whom no other conventional therapy exists~3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 for all tumors~4. Subjects must have the following laboratory values:~   ・Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L~  * Hemoglobin (Hgb) ≥ 9 g/dL, drawn at least 7 days after the last RBC transfusion~  * Platelets (Plt) ≥ 100 x 109/L, drawn at least 7 days after the last platelet transfusion~  * Potassium within normal limits or correctable with supplements~  * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) or ≤ 5.0 x ULN if liver tumors are present~  * Serum bilirubin ≤ 1.5 x ULN; subjects with serum bilirubin \>1.5 x ULN and ≤ 2 x ULN may be enrolled if agreed to by the sponsor~  * Serum creatinine ≤ ULN or 24-hour clearance ≥ 50 mL/min~  * Negative serum pregnancy test in females of childbearing potential as per the CC-122 Pregnancy Prevention Rist Management Plan~5. Able to adhere to the study visit schedule and other protocol requirements~6. Must adhere to the Pregnancy Prevention Rist Management Plan~Exclusion Criteria:~1. Subjects with primary central nervous system (CNS) malignancies or symptomatic central nervous system metastases. Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed~2. Known acute or chronic pancreatitis~3. Any peripheral neuropathy ≥ NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Grade 2~4. Persistent diarrhea or malabsorption ≥ NCI CTCAE Grade 2, despite medical management~5. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:~   * Left Ventricular Ejection Fraction (LVEF) \< 45% as determined by Multiple Gated Acquisition Scan (MUGA) scan or Echocardiogram (ECHO)~  * Complete left bundle branch, or bifascicular block~     * Congenital long QT syndrome~    * Persistent or uncontrolled ventricular arrhythmias or atrial fibrillation~    * QTcF \> 460 msec on screening electrocardiogram (ECG) (mean of triplicate recordings)~    * Unstable angina pectoris or myocardial infarction ≤ 3 months prior to starting CC-122~    * Troponin-T value \>0.4 ng/mL or Brain Natriuretic Peptide (BNP) \>300 pg/mL Subjects with baseline troponin-T \>ULN or BNP \>100 pg/mL are eligible but must and optimization of cardioprotective therapy.~  * Other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mmHg)~6. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks, whichever is shorter, prior to starting CC-122 or who have not recovered from side effects of such therapy. Luteinizing hormone-releasing hormone (LHRH) agonists will be allowed for subjects with metastatic prostate cancer~7. Major surgery ≤ 2 weeks prior to starting CC-122 or still recovering from post operative side effects~8. Women who are pregnant or breast feeding. Adults of reproductive potential not employing two forms of birth control as per Pregnancy Prevention Risk Management Plan (PPRMP)~9. Known human immunodeficiency virus (HIV) infection~10. Known acute or chronic hepatitis B or C virus infection~11. Status post solid organ transplant~12. Less than 100 days for subjects receiving autologous hematologic stem cell transplant (HSCT); or 6 months for subjects receiving allogeneic HSCT, or if otherwise not fully recovered from HSCT-related toxicity~    a. The 6-month exclusionary period for recovery from HSCT-associated toxicity, applies regardless of whether an autologous or allogeneic transplant was performed~13. Known hypersensitivity to any component of the formulation of CC-122~14. Any significant medical condition (including active or controlled infection or renal disease), laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study~15. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~16. Any condition that confounds the ability to interpret data from the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-122 (Type: EXPERIMENTAL): CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy